Post-earnings recap
Reported
Thu, Nov 4, 2021
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Despite missing on EPS expectations, TG Therapeutics' stock rose by 5.89%, indicating that investors may be optimistic about the company's long-term strategy. The management's commitment to their goals, despite current challenges, likely contributed to the positive stock reaction. However, the lack of revenue data and guidance may leave some investors cautious.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | -$0.65 | N/A | -17.12% |
| Revenue | N/A | N/A | N/A |
Management expressed concern over current market conditions but remains focused on their strategic objectives. They did not provide specific guidance for future quarters.
Management acknowledged the challenges faced this quarter.
They emphasized their commitment to long-term goals despite short-term setbacks.